IRIS
TINARI, Nicola
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 4.109
EU - Europa 3.962
AS - Asia 1.329
AF - Africa 9
Continente sconosciuto - Info sul continente non disponibili 9
SA - Sud America 9
OC - Oceania 8
Totale 9.435
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 4.101
IE - Irlanda 813
CN - Cina 727
IT - Italia 693
UA - Ucraina 635
SE - Svezia 551
FR - Francia 422
GB - Regno Unito 393
TR - Turchia 377
DE - Germania 206
IN - India 146
FI - Finlandia 102
BE - Belgio 56
VN - Vietnam 50
AT - Austria 28
PL - Polonia 14
NL - Olanda 10
EU - Europa 9
AU - Australia 8
IR - Iran 7
RU - Federazione Russa 7
CA - Canada 6
EG - Egitto 6
HK - Hong Kong 5
IL - Israele 5
CH - Svizzera 4
CZ - Repubblica Ceca 4
ES - Italia 4
GR - Grecia 4
JP - Giappone 4
PT - Portogallo 4
RO - Romania 4
ID - Indonesia 3
BG - Bulgaria 2
BR - Brasile 2
CL - Cile 2
CO - Colombia 2
LU - Lussemburgo 2
MX - Messico 2
SG - Singapore 2
TW - Taiwan 2
AR - Argentina 1
DZ - Algeria 1
HR - Croazia 1
LT - Lituania 1
LV - Lettonia 1
MA - Marocco 1
MK - Macedonia 1
PY - Paraguay 1
SC - Seychelles 1
UZ - Uzbekistan 1
VE - Venezuela 1
Totale 9.435
Salva come PNG Salva come JPEG
Città #
Chandler 983
Dublin 799
Jacksonville 760
Princeton 327
Southend 304
Nanjing 224
Izmir 216
Ann Arbor 178
Ashburn 176
Beijing 160
Chieti 153
Wilmington 147
Dearborn 134
Altamura 124
Cambridge 112
Boardman 86
Nanchang 75
New York 64
Woodbridge 58
Brussels 56
Dong Ket 50
Shenyang 35
Hebei 34
Kunming 30
Rome 30
Norwalk 29
Vienna 28
Jiaxing 27
Tianjin 27
Falls Church 24
Washington 24
Pescara 21
Changsha 20
Houston 19
Montesilvano 17
Grevenbroich 15
Hangzhou 15
Lanzhou 14
Seattle 14
Kraków 13
Lanciano 13
San Mateo 13
Kocaeli 12
Pune 12
Changchun 11
Giaveno 10
L’Aquila 10
Düsseldorf 9
Guangzhou 9
Milan 9
Auburn Hills 8
Augusta 8
Leawood 8
Tappahannock 8
Ardabil 7
Chicago 7
Los Angeles 7
Redwood City 7
San Vito Chietino 7
Cairo 6
Edinburgh 6
Jinan 6
London 6
Menlo Park 6
Ningbo 6
Oklahoma City 6
Vittuone 6
Andover 5
Carini 5
Helsinki 5
Mumbai 5
Orange 5
Simi Valley 5
Anzio 4
Collecorvino 4
Denver 4
Fairfield 4
Garden City 4
Giulianova 4
Hefei 4
Hong Kong 4
Loma Linda 4
Madrid 4
Napoli 4
Perth 4
Shanghai 4
Spoltore 4
Ameno 3
Bari 3
Cedar Knolls 3
Città Sant'Angelo 3
Keputih 3
L'aquila 3
Leicester 3
Mcallen 3
Monmouth Junction 3
Pusiano 3
Savigliano 3
Shaoxing 3
Sulmona 3
Totale 5.970
Salva come PNG Salva come JPEG
Nome #
A phase I study of recombinant interferon-alpha administered as a seven-day continuous venous infusion at circadian-rhythm modulated rate in patients with cancer. 101
90K (Mac-2 BP) and galectins in tumor progression and metastasis. 95
A comparative study of the antiinflammatory, anticoagulant, antiangiogenic, and antiadhesive activities of nine different fucoidans from brown seaweeds 94
The 90K protein increases major histocompatibility complex class I expression and is regulated by hormones, gamma-interferon, and double-strand polynucleotides. 94
A phase II study of dose-dense epirubicin plus cyclophosphamide followed by docetaxel plus capecitabine and pegfilgrastim support as preoperative therapy for patients with stage II, IIIA breast cancer. 93
The 90K tumor associated antigen and clinical progression in human immunodeficiency virus infection 92
Glicomimetici quali potenziali nuovi farmaci per la prevenzione delle metastasi. 91
Neoadjuvant chemotherapy in triple-negative breast cancer: A multicentric retrospective observational study in real-life setting 91
High expression of 90K (Mac-2 BP) is associated with poor survival in node-negative breast cancer patients not receiving adjuvant systemic therapies 91
Breast cancer "tailored follow-up" in Italian oncology units: A web-based survey 91
Occupational allergy: is there a role for nanoparticles? 90
Purification and characterization of a 90 kDa protein releasedfrom human tumors and tumor cell lines 89
ERBB3 BINDING ANTIBODY 85
Elevated serum levels of 90K/MAC-2BP predict unresponsiveness to alfa-interferon therapy in chronic HCV hepatitis patients 82
Long-term outcome of neoadjuvant endocrine therapy with aromatase inhibitors in elderly women with hormone receptor-positive breast cancer 82
Inhibition of tumor growth and angiogenesis by SP-2, an anti-lectin, galactoside-binding soluble 3 binding protein (LGALS3BP) antibody. 82
The Benzimidazole-Based Anthelmintic Parbendazole: A Repurposed Drug Candidate That Synergizes with Gemcitabine in Pancreatic Cancer 82
Sunitinib malate (SU-11248) alone or in combination with low-dose docetaxel inhibits the growth of DU-145 prostate cancer xenografts. 81
Unknown primary tumors 80
Principali effetti collaterali delle terapie mediche 80
Prognostic relevance of LGALS3BP in human colorectal carcinoma 80
null 79
An Epigenetic Approach to Pancreatic Cancer Treatment: the Prospective Role of Histone Deacetylase Inhibitors 78
A novel serum test using interferon for early detection of tumor reccurrence in cancer patients after radical surgery. 77
A novel serum test using interferon for early detection of tumor reccurrence in cancer patients after radical surgery 77
Effect of Gender on the Outcome of Patients Receiving Immune Checkpoint Inhibitors for Advanced Cancer: A Systematic Review and Meta-Analysis of Phase III Randomized Clinical Trials 77
Do cut-off values of lymph node ratio and presence of perineural invasion affect survival in breast cancer patients with pathologic N3a lymph node stage? Reply to Kadri Altundag 76
Gli analoghi sintetici delle glicoamine come potenziali nuovi farmaci nella prevenzione delle metastasi 75
Identification of Subgroups of Early Breast Cancer Patients at High Risk of Nonadherence to Adjuvant Hormone Therapy: Results of an Italian Survey 75
Developing a Decision-making Model Based on an Interdisciplinary Oncological Care Group for the Management of Colorectal Cancer 74
Timed flat infusion of 5-fluorouracil increases the tolerability of 5-fluorouracil/docetaxel regimen in metastatic breast cancer: a dose-finding study. 73
Relief of symptoms after gefitinib is associated with improvement of rest/activity rhythm in advanced lung cancer 73
A 90-kDa protein serum marker for the prediction of progression to AIDS in a cohort of HIV-1+ homosexual men. 73
90k is a serum marker of poor-prognosis in non-hodgkins-lymphoma patients. 73
Long-term outcome of neoadjuvant systemic therapy for locally advanced breast cancer in routine clinical practice. 73
Prognostic value of a novel circulating serum 90K antigen in breast cancer 72
Role of 90K protein in asthma and TH2-type cytokine expression. 72
Upstream stimulatory factor regulates constitutive expression and hormonal suppression of the 90K (Mac-2BP) protein. 72
Long-term outcome of breast cancer patients with pathologic N3a lymph node stage 72
Effects of repurposed drug candidates nitroxoline and nelfinavir as single agents or in combination with erlotinib in pancreatic cancer cells 72
Weight loss and body mass index in advanced gastric cancer patients treated with second-line ramucirumab: a real-life multicentre study 72
PLC-gamma-1 phosphorylation status is prognostic of metastatic risk in patients with early-stage Luminal-A and -B breast cancer subtypes 72
Outcomes of HER2-positive early breast cancer patients in the pre-trastuzumab and trastuzumab eras: a real-world multicenter observational analysis. The RETROHER study 71
A multicenter study of body mass index in cancer patients treated with anti-PD-1/PD-L1 immune checkpoint inhibitors: when overweight becomes favorable 71
A Case of Stage I Vulvar Squamous Cell Carcinoma with Early Relapse and Rapid Disease Progression 71
Exosomes as pleiotropic players in pancreatic cancer 71
Prognostic value of 90K protein in HIV infection 70
Preoperative dose-dense sequential chemotherapy of epirubicin/cyclophosphamide followed by docetaxel/capecitabine in patients with breast cancer 70
null 70
Effect of targeted agents on the endocrine response of breast cancer in the neoadjuvant setting: A systematic review 70
Novel inhibitors of pvhl-elongin c binding 70
An FPSE-HPLC-PDA method for the determination of anticancer drugs in human whole blood, plasma, and urine 70
TGF-β-1 increases 90K tumor associated antigen gene expression by increasing upstream regulatory factor binding to the minimal promoter. 69
null 69
Adhesion to 90K (Mac-2 BP) as a mechanism for lymphoma drug resistance in vivo. 69
DNA ploidy and S-phase fraction in pulmonary carcinoids. 68
BIOLOGICAL INDICATORS OF PROGNOSIS IN HUMAN CANCER: AN EMERGING ROLE FOR LECTIN GALACTOSIDE-BINDING SOLUBLE 3-BINDING PROTEIN (LGALS3BP) 68
Lack of expression of galectin-3 is associated with a poor outcome in node-negative patients with laryngeal squamous-cell carcinoma. 67
Changes of topoisomerase IIalpha expression in breast tumors after neoadjuvant chemotherapy predicts relapse-free survival 67
Predictive value of skeletal muscle mass for immunotherapy with nivolumab in non-small cell lung cancer patients: A “hypothesis-generator” preliminary report 67
Elevated serum levels of a 90,000 daltons tumor-associated antigen in cancer and in infection by human immunodeficiency virus (HIV). 66
Clinical Outcomes of Patients with Advanced Cancer and Pre-Existing Autoimmune Diseases Treated with Anti-Programmed Death-1 Immunotherapy: A Real-World Transverse Study 66
Palbociclib plus endocrine therapy in HER2 negative, hormonal receptor-positive, advanced breast cancer: A real-world experience 66
Concentrations of Galectin-3 in the Sera of Normal Controls and Cancer Patients 65
Molecular mechanisms of endocrine resistance and their implication in the therapy of breast cancer 65
Impact of BMI on clinical outcome in advanced cancer patients treated with anti‑PD‑1 Immune checkpoint inhibitors: a preliminary analysis 65
A Flow cytometric study of early gastric cancer 64
Adjuvant anastrozole versus exemestane versus letrozole, upfront or after 2 years of tamoxifen, in endocrine-sensitive breast cancer (FATA-GIM3): a randomised, phase 3 trial 64
Circulating Cancer Stem Cell-Derived Extracellular Vesicles as a Novel Biomarker for Clinical Outcome Evaluation 64
A PHASE II STUDY OF NEOADJUVANT CHEMOTHERAPY WITH CISTAPLIN, EPIRUBICIN AND VP – 16 FOR STAGE III UNRESECTABLE NON-SMALL CELL LUNG CANCER 62
Elevated serum level of a 90,000 daltons tumor-associated antigen in cancer and infection by Human Immunodeficiency Virus ( HIV) 62
New Targets for Therapy in Pancreatic Cancer 62
Tumor-derived microvesicles: The metastasomes. 62
Inhibition of tumor growth and angiogenesis by SP-2, an anti-LGALS3BP antibody 62
A Stochastic Model for the HIV/AIDS Dynamic Evolution 61
Neoadjuvant Sequential Docetaxel Followed by High-Dose Epirubicin in Combination With Cyclophosphamide Administered Concurrently With Trastuzumab. The DECT Trial 61
FPSE-HPLC-PDA METHOD FOR THE DETERMINATION OF INFLAMMATORY BOWEL DISEASE TREATMENT DRUGS IN WHOLE BLOOD, PLASMA AND URINE 61
Neoadjuvant Chemotherapy for Surgically Staged IIIA N2 Non-Small Cell Lung Cancer (NSCLC) in the Elderly 60
Chronomodulated infusion of cisplatin, 5-fluorouracil and folinic acid: lack of activity in advanced colorectal cancer. 60
Synthetic lactulose amines: novel class of anticancer agents that induce tumor-cell apoptosis and inhibit galectin-mediated homotypic cell aggregation and endothelial cell morphogenesis. 60
Lack of prognostic value of immunohistochemical determination of epidermal growth-factor receptors in human prostate-cancer. 60
Prognostic value of a novel circulating serum 90K antigen in HIV-infected haemophilia patients. 60
Pancreatic juice 90K and serum CA 19-9 combined determination can discriminate between pancreatic cancer and chronic pancreatitis. 59
Synthetic Inhibitors of Galectin-1 and -3 Selectively Modulate Homotypic Cell Aggregation and Tumor Cell Apoptosis 59
Dynamic test with recombinant interferon-alpha-2b: effect on 90K and other tumour-associated antigens in cancer patients without evidence of disease. 59
DNA and S-phase fraction analysis by flow cytometry in prostate cancer. Clinicopathologic implications. 59
LGALS3BP, A TUMOR-ASSOCIATED ANTIGEN, UPREGULATES VEGF IN HUMAN BREAST CANCER: POSSIBLE IMPLICATIONS IN ANGIOGENESIS 59
Immunotherapy in HER2-positive breast cancer: state of the art and future perspectives 59
Corrigendum to "Circulating Cancer Stem Cell-Derived Extracellular Vesicles as a Novel Biomarker for Clinical Outcome Evaluation" 59
Impact of primary tumor location in patients with RAS wild-type metastatic colon cancer treated with first-line chemotherapy plus anti-EGFR or anti-VEGF monoclonal antibodies: A retrospective multicenter study 59
Expression of the 90K tumor-associated protein in benign and malignant melanocytic lesions. 58
Triplet schedule of weekly 5-fluorouracil and alternating irinotecan or oxaliplatin in advanced colorectal cancer: A dose-finding study 58
Fabric Phase Sorptive Extraction-High Performance Liquid Chromatography-Photo Diode Array Detection Method for Simultaneous Monitoring of Three Inflammatory Bowel Disease Treatment Drugs in Whole Blood, Plasma and Urine 58
Allergooncology: an expanding research area 58
Combinations of biological response modifiers: rationale and clinical responses. 57
Triplet Chemotherapy in Patients With Metastatic Colorectal Cancer: Toward the Best Way to Safely Administer a Highly Active Regimen in Clinical Practice 57
EV20, a Novel Anti-ErbB-3 Humanized Antibody, Promotes ErbB-3 Down-Regulation and Inhibits Tumor Growth In Vivo. 57
null 57
Weighing the role of skeletal muscle mass and muscle density in cancer patients receiving PD-1/PD-L1 checkpoint inhibitors: a multicenter real-life study 57
HCV genotype and serum 90K levels: host and virus related factors predict response to a-ifn therapy 56
Totale 7.074
Salva come PNG Salva come JPEG
Categoria #
all - tutte 33.019
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 33.019
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2018/2019287 0 0 0 0 0 0 0 0 0 13 13 261
2019/20201.991 580 106 29 69 146 137 222 152 112 214 204 20
2020/20211.066 149 13 177 19 80 193 43 30 71 129 70 92
2021/2022906 35 22 15 175 79 37 35 70 59 22 100 257
2022/20232.755 222 349 206 312 276 496 150 240 306 22 114 62
2023/20241.245 125 46 85 71 89 480 242 55 41 11 0 0
Totale 10.062